JP2022540610A - がん細胞に結合し、放射性核種を前記細胞にターゲティングする抗体 - Google Patents

がん細胞に結合し、放射性核種を前記細胞にターゲティングする抗体 Download PDF

Info

Publication number
JP2022540610A
JP2022540610A JP2022501132A JP2022501132A JP2022540610A JP 2022540610 A JP2022540610 A JP 2022540610A JP 2022501132 A JP2022501132 A JP 2022501132A JP 2022501132 A JP2022501132 A JP 2022501132A JP 2022540610 A JP2022540610 A JP 2022540610A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
acid sequence
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022501132A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540610A5 (cg-RX-API-DMAC7.html
Inventor
パブロ ウマーニャ,
ザビーネ イムホフ-ユング,
アレクサンダー ハース,
クリスティアン クライン,
ソフィア フロスト,
フェリックス ボルマン,
ギー ジョルジュ,
セバスチャン フェン,
フロリアン リップスマイヤー,
ダニエラ マチェコ,
イェルク メレケン,
バルバラ ヴァイザー,
Original Assignee
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2022540610A publication Critical patent/JP2022540610A/ja
Publication of JP2022540610A5 publication Critical patent/JP2022540610A5/ja
Priority to JP2025139960A priority Critical patent/JP2026000913A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2022501132A 2019-07-12 2020-07-10 がん細胞に結合し、放射性核種を前記細胞にターゲティングする抗体 Withdrawn JP2022540610A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025139960A JP2026000913A (ja) 2019-07-12 2025-08-25 がん細胞に結合し、放射性核種を前記細胞にターゲティングする抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19186135 2019-07-12
EP19186135.0 2019-07-12
PCT/EP2020/069561 WO2021009047A1 (en) 2019-07-12 2020-07-10 Antibodies which bind to cancer cells and target radionuclides to said cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025139960A Division JP2026000913A (ja) 2019-07-12 2025-08-25 がん細胞に結合し、放射性核種を前記細胞にターゲティングする抗体

Publications (2)

Publication Number Publication Date
JP2022540610A true JP2022540610A (ja) 2022-09-16
JP2022540610A5 JP2022540610A5 (cg-RX-API-DMAC7.html) 2024-05-20

Family

ID=67262219

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022501132A Withdrawn JP2022540610A (ja) 2019-07-12 2020-07-10 がん細胞に結合し、放射性核種を前記細胞にターゲティングする抗体
JP2025139960A Pending JP2026000913A (ja) 2019-07-12 2025-08-25 がん細胞に結合し、放射性核種を前記細胞にターゲティングする抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025139960A Pending JP2026000913A (ja) 2019-07-12 2025-08-25 がん細胞に結合し、放射性核種を前記細胞にターゲティングする抗体

Country Status (18)

Country Link
US (1) US20220267463A1 (cg-RX-API-DMAC7.html)
EP (1) EP3997130A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022540610A (cg-RX-API-DMAC7.html)
KR (1) KR20220034208A (cg-RX-API-DMAC7.html)
CN (1) CN114341188A (cg-RX-API-DMAC7.html)
AR (2) AR119382A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020313285A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000481A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143464A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000052A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022001021A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220061A (cg-RX-API-DMAC7.html)
IL (1) IL289040A (cg-RX-API-DMAC7.html)
MX (1) MX2022000379A (cg-RX-API-DMAC7.html)
PE (1) PE20220596A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550035A1 (cg-RX-API-DMAC7.html)
TW (1) TW202115117A (cg-RX-API-DMAC7.html)
WO (1) WO2021009047A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022008688A1 (en) * 2020-07-10 2022-01-13 F. Hoffmann-La Roche Ag Antibodies which bind to cancer cells and target radionuclides to said cells
PE20240690A1 (es) * 2021-01-12 2024-04-10 Hoffmann La Roche Anticuerpos split que se unen a celulas cancerosas y dirigen radionuclidos a dichas celulas
WO2025165830A1 (en) * 2024-01-30 2025-08-07 Wisconsin Alumni Research Foundation Compositions and methods for targeting cell surface markers induced by radiation therapy
IL330142A (en) 2024-02-20 2026-08-01 F Hoffmann La Roche Ag New Antibodies for Pre-Targeting and Their Uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505319A (ja) * 2012-01-13 2015-02-19 ユリウス−マクシミリアンズ−ウニヴェルジテート ウュルツブルグ 二重抗原誘導型の二部分機能相補
JP2017530102A (ja) * 2014-08-29 2017-10-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 腫瘍を標的としたil−2バリアント免疫サイトカインとヒトpd−l1に対する抗体との併用療法
WO2019122350A1 (en) * 2017-12-21 2019-06-27 Gernot Stuhler Specific dosage regimen for hemibody therapy

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
GB9221657D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
EP1049787B1 (en) * 1998-01-23 2004-11-24 Vlaams Interuniversitair Instituut voor Biotechnologie Multipurpose antibody derivatives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE60023451T2 (de) 1999-02-05 2006-07-20 Therapeutic Human Polyclonals, Inc., Mountain View Aus nicht-menschlichen transgenen tieren gewonnene menschliche polyklonale antikörper
CA2378403A1 (en) 1999-07-26 2001-02-01 Genentech, Inc. Novel polynucleotides and method for the use thereof
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
IL154751A0 (en) 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
MXPA06000562A (es) 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
DE602004027291D1 (de) 2003-11-25 2010-07-01 Us Gov Health & Human Serv Mutierte anti-cd22-antikörper und immunkonjugate
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080184380A1 (en) 2004-10-22 2008-07-31 Therapeutic Human Polyclonals Inc. Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals
BRPI0607315B1 (pt) 2005-02-07 2022-05-17 Roche Glycart Ag Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
ES2347979T3 (es) 2005-08-03 2010-11-26 Therapeutic Human Polyclonals, Inc. Supresion de la apoptosis en linfocitos b en animales transgenicos que expresan inmunoglobulina humanizada.
WO2007071422A2 (en) 2005-12-21 2007-06-28 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
EP2064325B1 (en) 2006-09-01 2011-12-07 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
AU2009246640A1 (en) * 2008-05-15 2009-11-19 Biogen Idec Ma Inc. Anti-Fn14 antibodies and uses thereof
EP2403530B1 (en) 2009-02-27 2016-05-11 Massachusetts Institute of Technology Engineered proteins with high affinity for dota chelates
CN102712696A (zh) 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
KR101981342B1 (ko) 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea 항체
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
KR102069397B1 (ko) 2012-02-15 2020-01-22 에프. 호프만-라 로슈 아게 Fc-수용체 기재 친화성 크로마토그래피
CN110437337B (zh) 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
ES2763429T5 (es) * 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
JP6829194B2 (ja) 2014-10-24 2021-02-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Vh−vlドメイン間角度に基づく抗体ヒト化の方法
ES2788979T3 (es) 2014-11-14 2020-10-23 Hoffmann La Roche Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
JP7044700B2 (ja) 2015-10-02 2022-03-30 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ceaxcd3 t細胞活性化抗原結合分子
HUE054131T2 (hu) * 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
ES3057687T3 (en) * 2017-07-06 2026-03-04 Memorial Sloan Kettering Cancer Center Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
KR102884852B1 (ko) * 2018-04-16 2025-11-14 에프. 호프만-라 로슈 아게 킬레이트화된 방사성핵종에 대한 항체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505319A (ja) * 2012-01-13 2015-02-19 ユリウス−マクシミリアンズ−ウニヴェルジテート ウュルツブルグ 二重抗原誘導型の二部分機能相補
JP2017530102A (ja) * 2014-08-29 2017-10-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 腫瘍を標的としたil−2バリアント免疫サイトカインとヒトpd−l1に対する抗体との併用療法
WO2019122350A1 (en) * 2017-12-21 2019-06-27 Gernot Stuhler Specific dosage regimen for hemibody therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Design of split superantigen fusion proteins for cancer immunotherapy", JBC PAPERS IN PRESS, vol. Manuscript RA118.006742, JPN6024027741, 19 February 2019 (2019-02-19), pages 1 - 20, ISSN: 0005583543 *
PROTEIN ENGINEERING, DESIGN & SELECTION, vol. 26, no. 3, JPN6024027742, 2013, pages 187 - 193, ISSN: 0005583544 *

Also Published As

Publication number Publication date
AR122930A1 (es) 2022-10-19
CA3143464A1 (en) 2021-01-21
PH12022550035A1 (en) 2023-04-03
CL2022000052A1 (es) 2022-10-21
MX2022000379A (es) 2022-02-10
AR119382A1 (es) 2021-12-15
CR20220061A (es) 2022-04-20
WO2021009047A1 (en) 2021-01-21
AU2020313285A1 (en) 2022-02-17
TW202115117A (zh) 2021-04-16
IL289040A (en) 2022-02-01
CO2022001021A2 (es) 2022-04-29
US20220267463A1 (en) 2022-08-25
BR112022000481A2 (pt) 2022-03-08
CN114341188A (zh) 2022-04-12
PE20220596A1 (es) 2022-04-22
JP2026000913A (ja) 2026-01-06
EP3997130A1 (en) 2022-05-18
KR20220034208A (ko) 2022-03-17

Similar Documents

Publication Publication Date Title
US20260015436A1 (en) Antibodies for chelated radionuclides
JP7582867B2 (ja) キレート化された放射性核種に対する抗体および除去剤
JP2026000913A (ja) がん細胞に結合し、放射性核種を前記細胞にターゲティングする抗体
JP2026071214A (ja) がん細胞に結合し、当該細胞に対して放射性ヌクレオチドを標的化する抗体
US20240173442A1 (en) Combination therapy
US20240082437A1 (en) Split antibodies which bind to cancer cells and target radionuclides to said cells
RU2833191C2 (ru) Антитела, которые связываются с раковыми клетками и обеспечивают направленный перенос радионуклидов к указанным клеткам
RU2833233C2 (ru) Антитела к хелатным радионуклидам
HK40063708A (en) Antibodies which bind to cancer cells and target radionuclides to said cells
HK40093537A (en) Split antibodies which bind to cancer cells and target radionuclides to said cells
HK40083267A (en) Antibodies which bind to cancer cells and target radionuclides to said cells
RU2852663C1 (ru) Антитела против cd3 и bcma и биспецифичные связывающие белки, полученные из них

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240509

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250430

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250827